PlainRecalls
CriticalClass ITerminated

FDA Drug recall · Reported April 7, 2021

Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 20mL Single-Dose Vials per pack NDC 68382-049-10, Rx only, Manufactured by: Cadila Healthcare Ltd., Vadodara, India. Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.

Crystallization: customer complaints for crystallization in finished product.

Recall #
D-0315-2021
Affected scope
816 packs
Initiated
February 18, 2021
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Zydus Pharmaceuticals (USA) Inc recalled Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous I… - a critical-severity action.

Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous I… was recalled by Zydus Pharmaceuticals (USA) Inc in April 7, 2021. Reason: Crystallization: customer complaints for crystallization in finished product.. Check the official notice for the remedy. Verify recall #D-0315-2021 with the FDA Drug before acting.

The recall

Zydus Pharmaceuticals (USA) Inc issued this critical-severity FDA Drug recall-Crystallization: customer complaints for crystallization in finished product..

Critical
severity level
Class I
classification
April 7, 2021
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0315-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0315-2021) was formally reported on April 7, 2021, with the manufacturer initiating the action on February 18, 2021. It is classified under Critical severity (Class I), with a current status of Terminated. Zydus Pharmaceuticals (USA) Inc is listed as the recalling firm, operating out of Pennington, NJ. Federal records list the affected scope as 816 packs.

The documented reason for this recall is: Crystallization: customer complaints for crystallization in finished product. Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Critical

Affected scope

816 packs

Related Recalls

6

5 from same agency

Product description

Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 20mL Single-Dose Vials per pack NDC 68382-049-10, Rx only, Manufactured by: Cadila Healthcare Ltd., Vadodara, India. Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.

Reason for recall

Crystallization: customer complaints for crystallization in finished product.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Critical (Class I)
Status Terminated
Recall number D-0315-2021
Date reported April 7, 2021
Date initiated February 18, 2021
Recalling firm Zydus Pharmaceuticals (USA) Inc
Firm location Pennington, NJ
Affected scope 816 packs
Distribution USA Nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0315-2021) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • This is a Class I (high-risk) recall, stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 20mL Single-Dose Vials per pack NDC 68382-049-10, Rx only, Manufactured by: Cadila Healthcare Ltd., Vadodara, India. Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.. Recalled by Zydus Pharmaceuticals (USA) Inc. Units affected: 816 packs.
Why was this product recalled?
Crystallization: customer complaints for crystallization in finished product.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 7, 2021. Severity: Critical. Recall number: D-0315-2021.
Where was the recalled product distributed?
Distribution: USA Nationwide.
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0315-2021) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 7, 2021. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.